NCT00413205View on ClinicalTrials.gov

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

PHASE2CompletedINTERVENTIONAL
Enrollment

491

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Emphysema
Interventions
DRUG

Placebo

po daily

DRUG

RAR Gamma

5mg po daily

Trial Locations (64)

108

Reykjavik

1036

Budapest

1038

Riga

1431

Sofia

1606

Sofia

2006

Johannesburg

2045

Törökbálint

2118

Riga

2660

Balassagyarmat

4001

Durban

4126

eManzimtoti

4400

Nyíregyháza

5417

Daugavpils

5800

Pleven

6850

Worcester

7002

Rousse

7635

Pécs

7925

Cape Town

8001

Cape Town

9301

Bloemfontein

9700

Szombathely

16132

Genoa

19140

Philadelphia

27100

Pavia

29303

Spartanburg

31096

Haifa

35299

Birmingham

41100

Modena

49100

Petah Tikva

52621

Ramat Gan

56124

Pisa

60611

Chicago

73112

Oklahoma City

76100

Rehovot

77030

Houston

78306

Ashkelon

80206

Denver

83099

Donetsk

90502

Torrance

92103

San Diego

6423906

Tel Aviv

90095-1690

Los Angeles

48202-2689

Detroit

68198-2465

Omaha

390 03

Brno

360 09

Karlovy Vary

708 52

Ostrava

150 06

Prague

150 30

Prague

180 01

Prague

LV-1002

Riga

15-003

Bialystok

40-752

Katowice

92-215

Lodz

60-569

Poznan

60-693

Poznan

01-138

Warsaw

04-730

Warsaw

Unknown

Bellville

0157

Centurion

01133

Kiev

03680

Kiev

CV2 2DX

Coventry

L9 7AL

Liverpool

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00413205 - TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist) | Biotech Hunter | Biotech Hunter